AstraZeneca's Imfinzi Gets the US FDA Priority Review and BTD for LS-SCLC
Shots:
- Based on P-III (ADRIATIC) study data, AstraZeneca filled sBLA for Imfinzi and received the Priority Review and BTD in the US for LS-SCLC; regulatory decision is anticipated in Q4’24
- The study showed 27% reduction in death risk in Imfinzi participants vs. PBO; mOS was 55.9mos. vs. 33.4mos and 57% vs 48% of participants were alive at 3yrs.
- 24% reduction in disease progression/death was observed in Imfinzi participants vs. PBO; mPFS was 16.6mos. vs. 9.2mos.; 46% vs. 34% of participants had not experienced disease progression at 2yrs., safety profile was manageable & consistent
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca’s Lynparza Plus Imfinzi Receives the EC’s Approval to Treat Endometrial Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
